logo
更新:2024-05-10
医学总监/高级总监
6-9万
深圳南山区  | 10年  | 博士  | 社招
去申请
收藏
举报
职位详情
五险一金
通讯津贴
餐费补贴
扁平管理
弹性工作
带薪年假
年度旅游
节日礼物
定期体检
Main Responsibilities:
1.Contribute to clinical trial documentation development, including but not limited to clinical study protocol (synopsis), clinical study report, trial disclosure form, publication, etc.
2.Provide medical evaluation and support in early assessment, work out (as one of the key member) drug development strategy and clinical development plan.
3.Contribute to pre-IND/IND package preparation, application and communication with health authorities.
4.Take medical lead in clinical study implementation, and perform medical monitoring to ensure patients’ safety.
5.Contribute to NDA/BLA strategy, package preparation, submission and related communication with Health Authorities
6.Conduct KOL mapping and effectively communicate with KOL to maintain solid scientific relationship, understand Chinese clinical practice and clinical requirements.
7.Lead product life cycle management and new indications extension
8.Provide strategic support to products and company development, including but not limited to external collaboration.

Skill Requirements:
1.Doctor’s degree in Medicine with specialty training, or above
2.Over 10 years of experience in pharmaceutical industry environment, experience of new product launch of Metabolic disease is preferred.
3.Well established TA medical knowledge and well-understood to regulatory guidance for ICH/GCP
4.Experience of clinical study design, medical monitoring, CSR authoring, new drug early assessment, health authority communication is preferred
5.Academic network in related TA is a plus
6.Well-developed of time management skill and ability to determine and prioritize workload
7.Well-developed of other soft skill including but not limited to presentation, analytical and interpersonal skills
8.Strong business acumen, master of business administration is a plus.

其他信息
语言要求:英语、普通话
工作地址
深圳-南山区深圳国际创新谷
公司介绍
深圳君圣泰生物技术有限公司(简称“君圣泰”)成立于2011年,是一家原创新药研发公司。所开发药物拥有全球自主知识产权,专注于慢性肝病、消化系统和代谢疾病领域,特别是原发性硬化性胆管炎(PSC)、非酒精性脂肪性肝炎(NASH)和原发性胆汁性胆管严(PBC)等疾病,以满足尚未满足的临床需求。
公司在全球同步开发针对复杂疾病的First-in-Class创新药,通过其自主研发的FUSIONTX™️多机制化合物设计平台为临床提供更加安全和有效的解决方案。其旗舰品种HTD1801具有成药性高及安全性好的特点。
目前,公司获得2项中国“十三五新药创制重大专项”,并被FDA(美国食品药品监督管理局)授予2项FTD(快速审评通道资格认定)、1项ODD(孤儿药资格认定),有望加速药物审批,造福全球患者。
如欲了解公司更多信息,请浏览公司网站************************
工商信息
以下信息来自
企业类型
有限责任公司(台港澳法人独资)
经营状态
存续
行业类型
研究和试验发展
成立日期
2011年11月15日
注册地址
深圳市龙岗区吉华街道甘李二路11号中海信创新产业城18B栋1层02单元
统一社会信用代码
91440300581570844Y
若用人单位提供虚假招聘信息,以担保或其他任何名义收取财物,扣押或以保管为名索要证件,都属于违法行为,应当提高警惕。
发布于猎聘网